medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2022, Number 04

<< Back Next >>

Ginecol Obstet Mex 2022; 90 (04)

Predictors of the endometrium cancer recurrence

López-González E, Montero-Venegas F, Rojas-Luna JA

Language: Spanish
References: 15
Page: 316-322
PDF size: 293.97 Kb.


ABSTRACT

Objective: To determine which factors favor the prediction of endometrial cancer recurrence at different stages of the disease.
Materials and Methods: Retrospective study performed in a group of patients with endometrial cancer attended between 2017 and 2020 at the Juan Ramón Jiménez Hospital in Huelva, Spain. Analysis variables: age, degree of tumor differentiation, myometrial invasion, post-surgical stage and infiltration to the lymphovascular space, in all patients with recurrence. The statistical analysis was processed in SPSS v23. Having performed a Kolmogorov-Smirnov analysis and having obtained a non-normal result, a 2 test was used for parametric categorical data, and independently the Mann Whitney U test was used for non-parametric data. Values of p ‹ 0.01 were considered statistically significant.
Results: Nine patients with tumor recurrence and 5-year follow-up after primary diagnosis were collected. According to the statistical analysis, no dependency relationship was found between the variables recurrence and myometrial invasion (χ2 = 4.780; p = 0.092), recurrence and tumor grade (χ2= 7.765; p = 0.051) and recurrence and post-surgical stage (χ2 = 10.200, p = 0.070). In contrast, a dependency relationship was observed between the variables nodal involvement and positive lymphovascular space infiltration (χ2 = 9.954, Cc = 0.235, p ‹ 0.01). The existence of infiltration of the lymphovascular space was evaluated in all patients. This was negative in 141 cases and 4 of these cases had disease recurrence. 5 of 9 patients with disease recurrence had positive lymphovascular space infiltration.
Conclusions: The findings here show that more than half of the patients with disease recurrence have infiltration to the lymphovascular space and, in addition, if the infiltration to the lymphovascular space is negative, there is a 2.8% reduced risk of recurrence.


REFERENCES

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (5): E359-86. https://doi.org/10.1002/ijc.29210

  2. Marín JM ; Sandra Guerra S; Carmen Cuesta C; Miguel Martínez-Etayo M; Roberto Arina R, Iñaki Lete I. Abordaje laparoscópico del adenocarcinoma endometrioide de endometrio: resultados a corto y medio plazo. Prog Obstet Ginecol 2011, 54 (11): 563-67. doi:10.1016/j. pog.2011.07.004

  3. Denschlag D, Ulrich U, Emons G. The diagnosis and treatment of endometrial cancer: progress and controversies. Dtsch Arztebl Int. 2010;108 (34-35): 571-77. https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC3167060/

  4. Ortiz-Mendoza, C M; Velasco-Navarro, C. La obesidad: principal factor de riesgo para cáncer de endometrio. Rev Med Inst Mex Seguro Soc 2013; 51 (3): 260-63. https:// www.redalyc.org/pdf/

  5. Zhang H, Zuo Z, Wang Y, Wang L, Cohort study evaluating paraaortic lymphadenectomy in endometrial cancer. Oncol Lett 2012 ;4 (6): 1361-5. https://doi.org/10.3892/ol.2012.919

  6. Convery PA, Cantrell LA, Di Santo N, Broadwater G, et al. Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma. Gynecol Oncol 2011; 123 (1): 65-70. https://doi.org/10.1016/j.ygyno.2011.06.025

  7. Alay I, Turan T, Ureyen I, Karalok A, et al. Lymphadenectomy should be performed up to the renal vein in patients with intermediate-high risk endometrial cancer. Pathol Oncol Res 2015; 21 (3): 803-10. https://sci-hub.mksa. top/10.1007/s12253-014-9893-4

  8. Hahn HS, Lee IH, Kim TJ, Lee KH, et al. Lymphovascular space invasion is highly associated with lymph node metastasis and recurrence in endometrial cancer. Aust N Z J Obstet Gynaecol 2013; 53 (3): 293-7. https://doi.org/10.1111/ajo.12089

  9. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105 (2): 103-4. https://doi.org/10.1016/j.ijgo.2009.02.012

  10. Balagueró L, Comino R, Sainz de la Cuesta R, Jurado M, Xercavins J, Petschen I. Carcinoma de endometrio. Documento de Consenso SEGO. Madrid: Sociedad Española de Ginecología y Obstetricia 1999:. 91-136. https://doi. org/10.1016/j.gine.2009.03.009

  11. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 10 (29): 4783-91. https://doi.org/10.1200/JCO.2006.06.7173

  12. Sanhueza P, Oliva L. Eficiencia de los métodos diagnósticos en el estudio del sangrado uterino anormal en la peri y post menopausia. Rev Chil Obstet Ginecol 2008; 73 (1): 58-62. https://dx.doi.org/10.4067/S0717-75262008000100010

  13. Tabor A, Watt HC, Wald NJ. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol 2002; 99 (4): 663-70. https://doi.org/10.1016/S0029-7844(01)01771-9

  14. J.A. Lachance, E.N. Everett, B. Greer, L. Mandel, E. Swisher, H. Tamini, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2006; 101: 470-75. https://doi.org/10.1016/j.ygyno.2005.11.009

  15. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62 (4): 220-41. https://doi. org/10.3322/caac.21149




2020     |     www.medigraphic.com